Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL

[1]  M. Keating,et al.  Nelarabine , 2018, Nature Reviews Drug Discovery.

[2]  M. Relling,et al.  Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[4]  A. Ferrando,et al.  ETV6 mutations in early immature human T cell leukemias , 2011, The Journal of experimental medicine.

[5]  A. Hüttmann,et al.  High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. , 2011, Blood.

[6]  C. Eckert,et al.  Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[8]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[9]  Catherine L. Worth,et al.  SDM—a server for predicting effects of mutations on protein stability and malfunction , 2011, Nucleic Acids Res..

[10]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011 .

[11]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[13]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[14]  S. Hunger,et al.  Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group , 2009, Leukemia.

[15]  A. Ferrando,et al.  WT1 mutations in T-ALL. , 2009, Blood.

[16]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[17]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[18]  A. Ferrando,et al.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.

[19]  R. Larson,et al.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. , 2007, Blood.

[20]  A. Veerman,et al.  Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[21]  B. Mitchell,et al.  The 5'-nucleotidases as regulators of nucleotide and drug metabolism. , 2005, Pharmacology & therapeutics.

[22]  J. Kurtzberg,et al.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Chattopadhyay,et al.  Tumor Suppressor SMAR1 Activates and Stabilizes p53 through Its Arginine-Serine-rich Motif* , 2005, Journal of Biological Chemistry.

[24]  A. Scaloni,et al.  Mechanistic studies on bovine cytosolic 5'-nucleotidase II, an enzyme belonging to the HAD superfamily. , 2004, European journal of biochemistry.

[25]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[26]  T. Allio,et al.  Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway , 2003, Molecular and Cellular Biology.

[27]  C. Galmarini,et al.  Role of IMP-SELECTIVE 5′-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES , 2003, Leukemia & lymphoma.

[28]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[29]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[30]  P. Steinherz,et al.  Survival after relapse in childhood acute lymphoblastic leukemia , 1998, Cancer.

[31]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[32]  S. Inoue,et al.  Molecular cloning of human cytosolic purine 5'-nucleotidase. , 1994, Biochemical and biophysical research communications.

[33]  R. Pieters,et al.  Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. , 1992, Leukemia research.

[34]  T. Taylor.  A group experience. , 1990, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[35]  Mark L. Greenberg,et al.  Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. , 1990, The New England journal of medicine.

[36]  F. McCormick,et al.  N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. , 1990, Blood.

[37]  V. Madrid-Marina,et al.  High Km soluble 5'-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. , 1988, The Journal of biological chemistry.

[38]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.